Organicell Regenerative Medicine (BPSR) Stock Price, News & Analysis

Company Overview

Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR) is a biotechnology company focused on regenerative medicine and the development of biologic therapies intended to address inflammation, tissue injury and other medical conditions. The company’s research centers on acellular products derived from human perinatal tissues, including extracellular vesicles and exosomes that may support the body’s natural repair processes.

Organicell’s principal investigational product is Zofin, a non-cellular biologic preparation derived from human amniotic fluid. The company has studied Zofin and related technologies for potential applications involving inflammatory and degenerative conditions. These products remain subject to applicable regulatory requirements, and the company’s activities have primarily involved research, product development and clinical evaluation rather than the broad commercial sale of approved pharmaceuticals.

The company is based in the United States and has focused its operations and development efforts on the U.S. biotechnology and regenerative-medicine markets. Publicly available information about its current leadership, geographic operations and commercial partnerships is limited and may change over time.

Key Stats

• Today's Range: $1.21 to $1.25
• 50-Day Range: $1.15 to $1.67
• 52-Week Range: $0.04 to $0.63
• Volume: 2,970 shs
• Average Volume: 3.31 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:BPSR
• CIK: 1557376
• Web: organicell.com
• Phone: (888) 963-7881
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A